Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive surgery. Now, a new study offers hope of preventing hydrocephalus before it even occurs. The paper is published in the journal Molecular Therapy.
A tiny roundworm has helped University of Queensland scientists uncover minuscule structures in skin tissue that may protect the body’s ability to feel temperature, touch and pain. The research is published in Science Advances.
Cancer patients who suffer a heart attack face a dangerous mix of risks, which makes their clinical treatment particularly challenging. As a result, patients with cancer have been systematically excluded from many clinical trials and available risk scores. Until now, doctors had no standard tool to guide treatment in this vulnerable group.
Founded by three MIT alumni, Gensaic uses AI-guided protein design to deliver RNA and other therapeutic molecules to specific cells or areas of the body.
Veritas.AI is designed to advance the functionality of Spectrum Dynamics’ VERITON-CT scanner for nuclear imaging.
Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.
MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri® multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018.
ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ — Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advance catheter innovation with a focus on performance, design flexibility, and sustainability.
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company’s novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from Health Canada.
PITTSBURGH, Jan. 29, 2026 /PRNewswire/ — MolecuLight today announced that its MolecuLightDX® wound measurement has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT). The FDA’s MDDT program qualifies select, scientifically validated tools for use in medical device development and evaluation, enabling sponsors to generate reliable, FDA accepted data in clinical investigations.